SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): August 11, 2009
BioTime, Inc.
(Exact name of registrant as specified in its charter)
|
California |
1-12830 |
94-3127919 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
1301 Harbor Bay Parkway
Alameda, California 94502
(Address of principal executive offices)
(510) 521-3390
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Statements made in this Report that are not historical facts may constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed. Such risks and uncertainties include but are not limited
to those discussed in this report and in BioTime's Annual Report on Form 10-K filed with the Securities and Exchange Commission. Words such as “expects,” “may,” “will,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and similar expressions identify forward-looking statements.
Section 5 - Corporate Governance and Management
Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On August 11, 2009, we expanded the size of our Board of Directors to provide for an 11 director Board, and the Board elected Pedro Lichtinger as a director.
Pedro Lichtinger, 55, served as an executive of Pfizer, Inc. from 1995 to 2009, including as President of Pfizer’s Global Primary Care Unit from 2008 to 2009, Area President, Europe from 2006 to 2008, President, Global Animal Health from 1999 to 2006, and
Regional President Europe Animal Health from 1995 to 1999. Before joining Pfizer, Mr. Lichtinger was an executive of Smith Kline Beecham, last serving as Senior Vice President Europe from 1987 to 1995. Mr. Lichtinger holds an MBA degree from the Wharton School of Business and an Engineering degree from the National University of Mexico.
Compensation
As a non-employee director, Mr. Lichtinger will receive an Annual Fee of $15,000 in cash, plus $1,000 for each regular or special meeting of the Board of Directors he attends, and options to purchase 20,000 common shares under our 2002 Stock Option Plan, as amended.
The Annual Fee of cash will be paid, and the stock options granted will vest and become exercisable, in four equal quarterly installments, provided that the non-employee director remains a director on the last day of the applicable quarter. The options will expire if not exercised five years from the date
of grant. The exercise price of the options granted to Mr. Lichtinger is $3.45 per share.
Committees of the Board of Directors
On August 11, 2009, the Board of Directors selected directors to serve on the Audit Committee, the Nominating/Corporate Governance Committee, and the Compensation Committee.
The members of the Audit Committee are: Arnold I. Burns, Robert N. Butler, and Abraham E. Cohen. Mr. Burns will serve as Chairman of the Audit Committee.
2
The members of the Nominating/Corporate Governance Committee are Neal C. Bradsher, Robert N. Butler, and Abraham E. Cohen. Mr. Bradsher will serve as Chairman of the Nominating/Corporate Governance Committee.
The members of the Compensation Committee are: Arnold I. Burns, Robert N. Butler, and Pedro Lichtinger. Dr. Butler will serve as Chairman of the Compensation Committee.
Section 9 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits.
|
Exhibit Number |
Description | |
|
99.1 |
Press Release Dated August 17, 2009 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BIOTIME, INC. | |
|
Date: August 17, 2009 |
By /s/ Steven A. Seinberg |
|
Chief Financial Officer | |
3
|
Exhibit Number |
Description | |
|
99.1 |
Press Release Dated August 17, 2009 | |
4
Exhibit 99.1
|
BioTime, Inc. |
1301 Harbor Bay Parkway | |
|
Alameda, CA 94502 | ||
|
Tel: 510-521-3390 | ||
|
Fax: 510-521-3389 | ||
|
www.biotimeinc.com | ||
|
www.embryome.com |
BIOTIME, INC. APPOINTS PEDRO LICHTINGER
TO ITS BOARD OF DIRECTORS
ALAMEDA, CA, August 17, 2009 – BioTime, Inc. (OTCBB: BTIM) announced today that it had appointed Pedro Lichtinger to its board of directors.
Pedro Lichtinger, 55, served as an executive of Pfizer, Inc. from 1995 to 2009, including as President of Pfizer’s Global Primary Care Unit, Area President, Europe Pharmaceuticals, President, Global Animal Health, and Regional President Europe Animal Health. Before joining Pfizer, Mr. Lichtinger was an executive of Smith Kline
Beecham, last serving as Senior Vice President Europe Animal Health. Mr. Lichtinger has had broad international and cross functional experience and holds an MBA degree from the Wharton School of Business and an Engineering degree from the National University of Mexico.
“I am truly excited with the opportunity to be a part of BioTime and be able to contribute to the advancement of one of the leading companies in stem cell research and to have the opportunity to have a significant impact on the health and quality of life of patients around the world. I have been impressed with the quality of the Board
and with Michael D. West and I am delighted to join them in bringing the BioTime vision to life.”
“Mr. Lichtinger’s global experience in the pharmaceutical industry will benefit us as BioTime builds its business in the field of human embryonic stem cells and regenerative medicine,” said Michael D. West, Ph.D., BioTime’s CEO. “We look forward to working together to grow our business in the international
markets.”
About BioTime, Inc.
BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. BioTime develops and markets research products in the field of stem cells and regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. In addition to its
stem cell products, BioTime has developed blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment, and other applications. BioTime's lead product, Hextend®, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive
licensing agreements. Additional information about BioTime can be found on the web at www.biotimeinc.com.
Forward-Looking Statements
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products,
uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims
any intent or obligation to update these forward-looking statements.
Contact:
BioTime, Inc.
Judith Segall
jsegall@biotimemail.com
510-521-3390, ext 301
To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://www.b2i.us/irpass.asp?BzID=1152&to=ea&s=0